BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yalcin-Ozkat G. Molecular Modeling Strategies of Cancer Multidrug Resistance. Drug Resist Updat 2021;:100789. [PMID: 34973929 DOI: 10.1016/j.drup.2021.100789] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Caballero J. A new era for the design of TRPV1 antagonists and agonists with the use of structural information and molecular docking of capsaicin-like compounds. J Enzyme Inhib Med Chem 2022;37:2169-78. [PMID: 35975286 DOI: 10.1080/14756366.2022.2110089] [Reference Citation Analysis]
2 Li F, Yin J, Lu M, Mou M, Li Z, Zeng Z, Tan Y, Wang S, Chu X, Dai H, Hou T, Zeng S, Chen Y, Zhu F. DrugMAP: molecular atlas and pharma-information of all drugs. Nucleic Acids Res 2022:gkac813. [PMID: 36243961 DOI: 10.1093/nar/gkac813] [Reference Citation Analysis]
3 Liu GH, Chen T, Zhang X, Ma XL, Shi HS. Small molecule inhibitors targeting the cancers. MedComm (2020) 2022;3:e181. [PMID: 36254250 DOI: 10.1002/mco2.181] [Reference Citation Analysis]
4 Kumar A, Kalra S, Jangid K, Jaitak V. Flavonoids as P-glycoprotein inhibitors for multidrug resistance in cancer: an in-silico approach. J Biomol Struct Dyn 2022;:1-13. [PMID: 36120941 DOI: 10.1080/07391102.2022.2123390] [Reference Citation Analysis]
5 Matsuzaka Y, Uesawa Y. A Deep Learning-Based Quantitative Structure-Activity Relationship System Construct Prediction Model of Agonist and Antagonist with High Performance. Int J Mol Sci 2022;23:2141. [PMID: 35216254 DOI: 10.3390/ijms23042141] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]